Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China.

ABSTRACT:

Background

The recently completed INSPIRE trial demonstrated that iruplinalkib improved progression-free survival and intracranial antitumor activity compared with crizotinib in patients with anaplastic lymphoma kinase (ALK) -positive non-small-cell lung cancer (NSCLC). The objective of this study was to determine the potential cost-effectiveness of iruplinalkib vs. crizotinib in the Chinese healthcare setting.

Methods

A cost-effectiveness model was developed using the partition survival method, with three health states: progression-free survival, progressive disease, and death. Data from the INSPIRE trial were used to estimate progression-free and overall survival. Costs included drug treatment, disease management, and adverse events management. Drug costs and utilities wer

SUBMITTER: Zhang W 

PROVIDER: S-EPMC12580099 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature